Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY™, our proprietary biologics platform, to generate potentially first-in-class and best-in-class multi-specifics.
ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES results in ultra-high affinity, which translates to best-in-class potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of multi-specific biologics, with tunable half-life translating to the potential for quarterly or less frequent dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development, offering the potential to become the next-generation modality of choice. Learn more at www.attovia.com.
Company Details
- Employees
- 45
- Founded
- -
- Address
- 1091 Industrial Rd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.attovia.com/
- HQ
- San Carlos, California
Attovia Therapeutics Questions
Attovia Therapeutics's website is https://www.attovia.com/
Attovia Therapeutics's LinkedIn profile is https://www.linkedin.com/company/attovia-therapeutics
Attovia Therapeutics has
45 employees.
View email and phone details for 45
employees at Attovia Therapeutics.
Attovia Therapeutics's industry is
Biotechnology Research
Attovia Therapeutics's top competitors are
Tenvie Therapeutics,
Biosapien,
Curve Biosciences,
Aralez Bio,
Light Horse Therapeutics,
Avenzo Therapeutics,
Shinobi Therapeutics,
Siteone Therapeutics, Inc.,
Moonwalk Biosciences,
Futurehouse.
Attovia Therapeutics's categories are Biotechnology Research
Attovia Therapeutics's founding year is 2023
